FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B
- PMID: 29245009
- DOI: 10.1016/j.cell.2017.11.049
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B
Abstract
A phase 1/2 clinical trial of AAV-mediated gene therapy in patients with hemophilia B using an enhanced specific activity factor IX (FIX) transgene reports sustained levels of FIX levels, leading to the near elimination of bleeding for more than a year and without serious adverse side effects. These results are the best outcome to date for hemophilia gene therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538. N Engl J Med. 2017. PMID: 29211678 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
